中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Immune Responses and Protective Efficacy of Nanoemulsion-Adjuvanted Monkeypox Virus Recombinant Vaccines Against Lethal Challenge in Mice

文献类型:期刊论文

作者Zhang, Congcong1,3; Liu, Nuo1,3; Zhao, Yanqi2; Pan, Zhendong1,3; Wang, Dawei1,3; Tang, Wanda1,3; He, Yanhua1,3; Zheng, Xu1,3; Qi, Zhongtian1,3; Zhang, Xinxin2
刊名PATHOGENS
出版日期2025-12-16
卷号14期号:12页码:16
关键词monkeypox virus vaccinia virus recombinant vaccine nanoemulsion adjuvant neutralizing antibody lethal challenge histopathology
DOI10.3390/pathogens14121293
通讯作者Zhang, Xinxin(xinxinzhang@simm.ac.cn) ; Zhao, Ping(pnzhao@163.com)
英文摘要The ongoing global monkeypox outbreak since 2022 has highlighted the urgent need for vaccine development. Current vaccination strategies rely on cross-protective immunity provided by orthopoxvirus-based live-attenuated vaccines. However, these vaccines not only exhibit suboptimal efficacy against monkeypox virus (MPXV) but also raise safety concerns, particularly given the significant global overlap between MPXV infections and HIV. Owing to their superior safety profile and accessibility, recombinant subunit vaccines represent a highly promising platform for monkeypox vaccine development. In this study, we developed a subunit vaccine comprising A29L, B6R, and M1R antigens formulated with a proprietary nanoemulsion adjuvant and evaluated its immunogenicity and protective efficacy. In mice immunized with a prime-boost regimen of the three individual antigens combined with the nanoemulsion adjuvant, comparable serum IgG levels against each antigen were elicited. Both A29 and M1 formulations induced serum antibodies with potent neutralizing activity against MPXV and Vaccinia virus Western Reserve strain (VACV-WR). Notably, M1 antiserum exhibited stronger neutralization than A29 antiserum, whereas B6R immune serum showed no significant neutralizing activity. Splenocytes from B6R-immunized mice mounted a robust IFN-gamma response, which was markedly lower in those immunized with A29 or M1. All three monovalent vaccines conferred complete survival following an intranasal lethal MPXV challenge, with M1 providing the strongest protection. In a lethal VACV-WR challenge model, only M1 immunization conferred significant protection. Histopathological analysis of lung tissues on day 5 post-infection revealed more pronounced inflammatory features in B6R-immunized mice compared to the nanoemulsion adjuvant control group. Furthermore, the nanoemulsion-adjuvanted bivalent A29L + B6R formulation induced significantly higher IgG and neutralizing antibody titers and demonstrated superior protective efficacy compared to the aluminum hydroxide-adjuvanted formulation. This comparative preclinical evaluation provides important evidence to support the development of a safe and effective subunit vaccine against monkeypox.
资助项目National Key Research & Development Program of China[2022YFC2304100]
WOS研究方向Microbiology
语种英语
WOS记录号WOS:001646500700001
出版者MDPI
源URL[http://119.78.100.183/handle/2S10ELR8/322447]  
专题中国科学院上海药物研究所
通讯作者Zhang, Xinxin; Zhao, Ping
作者单位1.Naval Med Univ, Key Lab Biosafety Def, Minist Educ Peoples Republ China, Shanghai 200433, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
3.Naval Med Univ, Fac Naval Med, Dept Microbiol, Shanghai 200433, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Congcong,Liu, Nuo,Zhao, Yanqi,et al. Immune Responses and Protective Efficacy of Nanoemulsion-Adjuvanted Monkeypox Virus Recombinant Vaccines Against Lethal Challenge in Mice[J]. PATHOGENS,2025,14(12):16.
APA Zhang, Congcong.,Liu, Nuo.,Zhao, Yanqi.,Pan, Zhendong.,Wang, Dawei.,...&Zhao, Ping.(2025).Immune Responses and Protective Efficacy of Nanoemulsion-Adjuvanted Monkeypox Virus Recombinant Vaccines Against Lethal Challenge in Mice.PATHOGENS,14(12),16.
MLA Zhang, Congcong,et al."Immune Responses and Protective Efficacy of Nanoemulsion-Adjuvanted Monkeypox Virus Recombinant Vaccines Against Lethal Challenge in Mice".PATHOGENS 14.12(2025):16.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。